The stock of Diplomat Pharmacy Inc (NYSE:DPLO) is a huge mover today! About 882,481 shares traded hands or 36.14% up from the average. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 23.08% since February 26, 2016 and is downtrending. It has underperformed by 33.50% the S&P500.
The move comes after 6 months positive chart setup for the $1.78B company. It was reported on Oct, 1 by Barchart.com. We have $42.35 PT which if reached, will make NYSE:DPLO worth $925.60 million more.
Analysts await Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings on November, 1. They expect $0.24 EPS, down 7.69% or $0.02 from last year’s $0.26 per share. DPLO’s profit will be $15.33M for 29.02 P/E if the $0.24 EPS becomes a reality. After $0.23 actual EPS reported by Diplomat Pharmacy Inc for the previous quarter, Wall Street now forecasts 4.35% EPS growth.
Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage
Out of 8 analysts covering Diplomat Pharmacy (NYSE:DPLO), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Diplomat Pharmacy has been the topic of 11 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The rating was maintained by Mizuho on Wednesday, October 21 with “Buy”. Bank of America upgraded Diplomat Pharmacy Inc (NYSE:DPLO) on Wednesday, October 14 to “Neutral” rating. Cowen & Co initiated Diplomat Pharmacy Inc (NYSE:DPLO) on Friday, June 24 with “Market Perform” rating. On Tuesday, August 4 the stock rating was maintained by Leerink Swann with “Outperform”. Morgan Stanley downgraded the shares of DPLO in a report on Friday, October 2 to “Equal-Weight” rating. The company was maintained on Wednesday, May 11 by Mizuho. The firm has “Overweight” rating by Barclays Capital given on Wednesday, January 6. The firm earned “Neutral” rating on Tuesday, June 7 by Bank of America. As per Wednesday, October 21, the company rating was initiated by UBS.
According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”
Insitutional Activity: The institutional sentiment decreased to 1.43 in Q2 2016. Its down 0.22, from 1.65 in 2016Q1. The ratio is negative, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.
Northern Tru has invested 0.01% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Oberweis Asset Mgmt holds 2.47% or 237,515 shares in its portfolio. Teachers Retirement Of The State Of Kentucky, a Kentucky-based fund reported 15,700 shares. Swiss National Bank & Trust has 0% invested in the company for 64,400 shares. Cap Impact Advisors Ltd Co owns 32,768 shares or 0.54% of their US portfolio. The Ontario – Canada-based Royal Retail Bank Of Canada has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Invesco Ltd holds 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO) for 109,965 shares. State Of Wisconsin Board accumulated 267,900 shares or 0.04% of the stock. Tcw Group Inc Inc last reported 0.01% of its portfolio in the stock. Mirae Asset Invests holds 28,697 shares or 0.03% of its portfolio. Sentinel Asset Inc reported 216,849 shares or 0.18% of all its holdings. Credit Suisse Ag has 0% invested in the company for 46,796 shares. Ladenburg Thalmann Fincl Service has 1,565 shares for 0% of their US portfolio. Citigroup Inc holds 1,076 shares or 0% of its portfolio. Da Davidson And Comm holds 8,225 shares or 0.01% of its portfolio.
Insider Transactions: Since April 15, 2016, the stock had 0 insider buys, and 4 sales for $2.15 million net activity. Another trade for 12,325 shares valued at $440,794 was sold by Kaddis Atheer A.
More notable recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Fool.com which released: “Why Diplomat Pharmacy, Inc. Shares Tumbled 12.9% in August” on September 13, 2016, also Fool.com with their article: “Organic Growth Powers Diplomat Pharmacy, Inc. in Q1” published on May 10, 2016, Fool.com published: “Why Diplomat Pharmacy, Inc. Shares Are Crashing Today” on March 01, 2016. More interesting news about Diplomat Pharmacy Inc (NYSE:DPLO) were released by: Fool.com and their article: “Organic Growth and Acquisitions Help Diplomat Pharmacy, Inc. in Q2” published on August 10, 2016 as well as Fool.com‘s news article titled: “Acquisitions Propel Diplomat Pharmacy, Inc. to Strong Q3” with publication date: November 04, 2015.
DPLO Company Profile
Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.